Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Published version of a preprint
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Most chimeric antigen receptor (CAR) T-cell strategies against glioblastoma have demonstrated only modest therapeutic activity and are based on persistent gene modification strategies that have limited transgene capacity, long manufacturing processes, and the risk for uncontrollable off-tumor toxicities. mRNA-based T-cell modifications are an emerging safe, rapid, and cost-effective alternative to overcome these challenges, but are underexplored against glioblastoma. Experimental Design: We generated mouse and human mRNA-based multifunctional T cells coexpressing a multitargeting CAR based on the natural killer group 2D (NKG2D) receptor and the proinflammatory cytokines IL12 and IFNα2 and assessed their antiglioma activity in vitro and in vivo. Results: Compared with T cells that either expressed the CAR or cytokines alone, multifunctional CAR T cells demonstrated increased antiglioma activity in vitro and in vivo in three orthotopic immunocompetent mouse glioma models without signs of toxicity. Mechanistically, the coexpression of IL12 and IFNα2 in addition to the CAR promoted a proinflammatory tumor microenvironment and reduced T-cell exhaustion as demonstrated by ex vivo immune phenotyping, cytokine profiling, and RNA sequencing. The translational potential was demonstrated by image-based single-cell analyses of mRNA-modified T cells in patient glioblastoma samples with a complex cellular microenvironment. This revealed strong antiglioma activity of human mRNA-based multifunctional NKG2D CAR T cells coexpressing IL12 and IFNα2 whereas T cells that expressed either the CAR or cytokines alone did not demonstrate comparable antiglioma activity. Conclusions: These data provide a robust rationale for future clinical studies with mRNA-based multifunctional CAR T cells to treat malignant brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, mRNA’s broad non-toxic dose range in T cells,27,33 enables co-expression of multiple functional proteins,32”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [32]
In the citing paper
“In-vitro-transcribed (IVT) mRNA offers a promising platform, combining transient, non-integrating mode of action with rapid protein expression and minimal cellular footprint.26,27,28,29,30,31,32”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [32]
In the citing paper
“Our findings demonstrate that IVT mRNA provides a transient, non-integrating platform, which mitigates theoretical safety concerns by avoiding risks of insertional mutagenesis and irreversible genomic alterations associated with viral vectors or CRISPR-Cas9 systems,11,12,13,14,18 while enabling sophisticated multiplexing strategies and potentially enhancing functional efficacy.28,29,30,31,32,45,65”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Residual Learning for Image Recognition
He, K., Zhang, X., Ren, S., & Sun, J. (2016) · 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) · doi:10.1109/cvpr.2016.90 · Cited by 235,474
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationmRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2311 · Cited by 133
Self-citation
Research works printed but not linked: 32
- Ostrom, 2020, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017, Neuro Oncol, 22, iv1, 10.1093/neuonc/noaa200 · DOI · Paper page
- Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497 · DOI · Paper page
- Ahmed, 2017, HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial, JAMA Oncol, 3, 1094, 10.1001/jamaoncol.2017.0184 · DOI · Paper page
- O'Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9, eaaa0984, 10.1126/scitranslmed.aaa0984 · DOI · Paper page
- Weiss, 2018, NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma, Cancer Res, 78, 1031, 10.1158/0008-5472.CAN-17-1788 · DOI · Paper page
- Yang, 2019, T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells, J Immunother Cancer, 7, 171, 10.1186/s40425-019-0642-9 · DOI
- Ponterio, 2020, Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture, Front Immunol, 11, 565631, 10.3389/fimmu.2020.565631 · DOI
- Yeku, 2017, Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment, Sci Rep, 7, 10541, 10.1038/s41598-017-10940-8 · DOI · Paper page
- Katlinski, 2017, Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment, Cancer Cell, 31, 194, 10.1016/j.ccell.2017.01.004 · DOI · Paper page
- Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 · DOI · Paper page
- Rafiq, 2020, Engineering strategies to overcome the current roadblocks in CAR T cell therapy, Nat Rev Clin Oncol, 17, 147, 10.1038/s41571-019-0297-y · DOI · Paper page
- Caruso, 2016, Redirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor, J Immunother, 39, 205, 10.1097/CJI.0000000000000126 · DOI
- Baumeister, 2019, Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma, Cancer Immunol Res, 7, 100, 10.1158/2326-6066.CIR-18-0307 · DOI · Paper page
- Zhang, 2005, Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy, Blood, 106, 1544, 10.1182/blood-2004-11-4365 · DOI · Paper page
- Tusup, 2019, Design of in vitro transcribed mRNA vectors for research and therapy, Chimia, 73, 391, 10.2533/chimia.2019.391 · DOI · Paper page
- Weiss, 2018, NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma, Clin Cancer Res, 24, 882, 10.1158/1078-0432.CCR-17-1766 · DOI
- Schuffler, 2013, TMARKER: a free software toolkit for histopathological cell counting and staining estimation, J Pathol Inform, 4, S2, 10.4103/2153-3539.109804 · DOI
- Friebel, 2020, Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes, Cell, 181, 1626, 10.1016/j.cell.2020.04.055 · DOI · Paper page
- Singer, 2016, A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells, Cell, 166, 1500, 10.1016/j.cell.2016.08.052 · DOI · Paper page
- Gunderson, 2020, TGFβ suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking, Nat Commun, 11, 1749, 10.1038/s41467-020-15404-8 · DOI · Paper page
- Snijder, 2017, Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study, Lancet Haematol, 4, e595, 10.1016/S2352-3026(17)30208-9 · DOI · Paper page
- Etxeberria, 2019, Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells, Cancer Cell, 36, 613, 10.1016/j.ccell.2019.10.006 · DOI
- Barber, 2009, Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment, J Immunol, 183, 6939, 10.4049/jimmunol.0902000 · DOI · Paper page
- Zhang, 2013, Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells, J Immunol, 190, 2455, 10.4049/jimmunol.1201314 · DOI
- Fujita, 2010, Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans, Clin Cancer Res, 16, 3409, 10.1158/1078-0432.CCR-10-0644 · DOI
- Happold, 2014, Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells, Mol Cancer Ther, 13, 948, 10.1158/1535-7163.MCT-13-0772 · DOI · Paper page
- Lohmann, 2020, Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity, Neurooncol Adv, 2, vdaa043
- Wakabayashi, 2018, JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma, J Neurooncol, 138, 627, 10.1007/s11060-018-2831-7 · DOI
- Agliardi, 2021, Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma, Nat Commun, 12, 444, 10.1038/s41467-020-20599-x · DOI · Paper page
- Chiocca, 2019, Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial, Sci Transl Med, 11, eaaw5680, 10.1126/scitranslmed.aaw5680 · DOI · Paper page
- Vom Berg, 2013, Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection, J Exp Med, 210, 2803, 10.1084/jem.20130678 · DOI · Paper page
- Pohl-Guimaraes, 2019, RNA-modified T cells mediate effective delivery of immunomodulatory cytokines to brain tumors, Mol Ther, 27, 837, 10.1016/j.ymthe.2018.10.007 · DOI
Cited by
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Drzeniek, N. M., Kahwaji, N., Picht, S., Dimitriou, I. M., Schlickeiser, S., Moradian, H., Geissler, S., Schmueck‐Henneresse, M., Gossen, M., & Volk, H. (2024) · Advanced Science · doi:10.1002/advs.202308447 · Cited by 18
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102929 · Cited by 7
Metadata
- Authors
- Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B. D., Snijder, B., Regli, L., Ravi, V. M., Heiland, D. H., Sentman, C. L., Weller, M., & Weiss, T.
- Affiliations
- 1Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- 2Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- 3Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany.
- 4Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
- 5Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- 6Microenvironment and Immunology Research Laboratory, Department of Neurosurgery, Medical Center, University of Freiburg, Breisgau, Germany.
- 8Center for Synthetic Immunity and Department of Microbiology & Immunology, Geisel School of Medicine, New Hampshire.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2022-08-29
- Volume
- 28
- Issue
- 21
- Pages
- 4747-4756
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 87
- References
- 7
- Language
- en
- Funders
- Swiss National Science Foundation (SNF 310030_170027)
- Swiss Cancer Research Foundation (KFS-4544-08-2018-R)
- Forschungskredit of the University of Zurich (FK-18-054)
- Betty and David Koetser Foundation for Brain Research
- Promedica Stiftung
- Helmut Horten Stiftung
- Clinical Research Priority Program of the University of Zurich
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-4384
- The paper
- Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B. D., Snijder, B., Regli, L., Ravi, V. M., Heiland, D. H., Sentman, C. L., Weller, M., & Weiss, T. (2022). Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-4384
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.